Fresenius SE Stock News

Over the last six months, Fresenius has seen the exit of its CEO, increasing activist exposure, and is reviewing the deconsolidation of its largest subsidiary Fresenius Medical Care. We view this deco

I've been buying Fresenius in small portions and adding to my position again and again over the past year. It's now more than 3% of my portfolio. While this company remains a long-term turnaround play

Fresenius SE is reporting mediocre results once again with Fresenius Medical Care struggling due to labor shortage and macroeconomic challenges. While Fresenius Medical Care and Fresenius Kabi are str

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q3 2022 Earnings Conference Call October 31, 2022 8:30 AM ET Company Participants Markus Georgi – Senior Vice President-Investor Relations Michael Sen – Chief

I've received plenty of inquiries with regards to Fresenius and its somewhat terrible performance YTD so far. Readers are asking if I'm "out" the company, or if I continue to believe that this company

FRANKFURT (Reuters) -Fresenius SE said its long-serving Chief Executive Stephan Sturm would quit, to be replaced by the head of its drugs unit, after the diversified group's earnings were hit followin

The shares of Fresenius, one of the world's largest healthcare groups, have been in a downward and then a sideways trend since 2017. Corona pandemic has been a major challenge, especially for its subs

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q2 2022 Earnings Conference Call July 28, 2022 7:30 AM ET Company Participants Markus Georgi - Senior Vice President of Investor Relations Stephan Sturm - Preside

We'll take a look at Fresenius in order to determine if the company still represents a good investment opportunity. Given a recent share price weakness, it's not strange that some investors are wonder

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q1 2022 Earnings Conference Call May 4, 2022 7:30 AM ET Company Participants Stephan Sturm – President & Chief Executive Officer Rachel Empey – Chief Financia

Fresenius is a diversified healthcare company. The company pays out a growing dividend.

Although Fresenius could raise its guidance and reported solid third quarter results, the stock declined pretty steeply in the last few weeks. Fresenius still has extremely high debt levels on its bal

Fresenius reported solid second quarter results with growing sales and growing earnings per share. The company is facing several problems - like high debt levels and the negative effects of COVID-19.

In this article, we're looking at the companies I consider the most investable for September of 2021. I look for investment-graded dividend-paying stocks with a conservative RoR of no less than 15% ov

German healthcare group Fresenius raised 2021 targets though it saw a weaker third quarter, saying progress on its cost-cutting plan should offset troubles at its dialysis unit.